We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.26 | 0.87% | 30.09 | 30.01 | 30.25 | 30.23 | 30.03 | 30.16 | 2,162,815 | 21:42:26 |
From May 2021 to May 2024
By Stephen Nakrosis
Genentech on Friday said the Food and Drug Administration approved its Tencentriq as an adjuvant treatment for certain lung cancer patients.
The company said Tencentriq, or atezolizumab, was approved as adjuvant treatment following surgery and platinum-based chemotherapy for certain adults with Stage II-IIIA non-small cell lung cancer.
Genentech said Tecentriq is the first and only cancer immunotherapy available for adjuvant treatment of NSCLC.
The company said the approval was based on results from interim analysis of the Phase III IMpower010 study, which showed treatment with Tecentriq improved disease-free survival by over one-third in PD-L1-positive Stage II-IIIA lung cancer, compared with the best supportive care.
Genentech is a member of the Roche Group.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
October 15, 2021 13:05 ET (17:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
